Top Markets
Coin of the day
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Classifica tra le azioni #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Prezzo delle azioni
$0.38
Ultima sincronizzazione: 2023-09-01
Capitalizzazione di mercato
$677.16K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Aceragen, Inc. (ACGN)

Categoria

Storico del rendimento da dividendi per Aceragen, Inc. (ACGN)
Il rendimento da dividendi (TTM) di Aceragen, Inc. (simbolo azionario: ACGN) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Aceragen, Inc. (ACGN) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.65%
BE